<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; USA</title>
	<atom:link href="http://www.tapanray.in/tag/usa/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>Is The Core Purpose of Pharma Business Much Beyond Profit Making?</title>
		<link>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=is-the-core-purpose-of-pharma-business-much-beyond-profit-making</link>
		<comments>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/#comments</comments>
		<pubDate>Mon, 10 Nov 2014 00:00:48 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Africa]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[antibiotics]]></category>
		<category><![CDATA[Banks]]></category>
		<category><![CDATA[BBC]]></category>
		<category><![CDATA[beyond]]></category>
		<category><![CDATA[big]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[Carmakers]]></category>
		<category><![CDATA[Chan]]></category>
		<category><![CDATA[Director]]></category>
		<category><![CDATA[Ebola]]></category>
		<category><![CDATA[expenditure. India]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[GlaxoSmithKline]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[margins]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[Media]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Oil&gas]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[PIL]]></category>
		<category><![CDATA[profit]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[pupose]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[West]]></category>
		<category><![CDATA[WHO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6164</guid>
		<description><![CDATA[Dr. Margaret Chan, the Director General of the World Health Organization (WHO), at a briefing to discuss the Ebola outbreak in West Africa at the UN Foundation in Washington on September 3, 2014 said: “Big Pharma&#8217;s greed for profits, not &#8230; <a href="http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/is-the-core-purpose-of-pharma-business-much-beyond-profit-making/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Drugs From The Same Indian Plant: Safe For Europe, Unsafe For America, Why?</title>
		<link>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why</link>
		<comments>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/#comments</comments>
		<pubDate>Mon, 09 Jun 2014 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[cGMP]]></category>
		<category><![CDATA[commissioner]]></category>
		<category><![CDATA[conspiracy]]></category>
		<category><![CDATA[Diovan]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EMA]]></category>
		<category><![CDATA[Europe]]></category>
		<category><![CDATA[Hamburg]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Lipitor]]></category>
		<category><![CDATA[Margaret]]></category>
		<category><![CDATA[nexium]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[plant]]></category>
		<category><![CDATA[Ranbaxy]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulators]]></category>
		<category><![CDATA[safe]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Theory]]></category>
		<category><![CDATA[Toansa]]></category>
		<category><![CDATA[unsafe]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[why]]></category>
		<category><![CDATA[wockhardt]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=5493</guid>
		<description><![CDATA[Good number of stories on US-FDA banning several drug manufacturing facilities of major domestic players of India over serious quality related issues, have been doing the rounds since about a year and almost at a regular interval. The quagmire has &#8230; <a href="http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/drugs-from-the-same-indian-plant-safe-for-europe-unsafe-for-america-why/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pioglitazone Conundrum: Should The Drug Regulator Step Over The Line?</title>
		<link>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line</link>
		<comments>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/#comments</comments>
		<pubDate>Mon, 08 Jul 2013 00:00:54 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Actos]]></category>
		<category><![CDATA[Agency]]></category>
		<category><![CDATA[assembly]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bladder]]></category>
		<category><![CDATA[canadian]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[claim]]></category>
		<category><![CDATA[combinations]]></category>
		<category><![CDATA[conundrum]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[diabetics]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[efficacy]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[FDA]]></category>
		<category><![CDATA[FDC]]></category>
		<category><![CDATA[flutter]]></category>
		<category><![CDATA[France]]></category>
		<category><![CDATA[French]]></category>
		<category><![CDATA[general]]></category>
		<category><![CDATA[Germany]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[increased]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indudtry]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[JAPI]]></category>
		<category><![CDATA[liability]]></category>
		<category><![CDATA[line]]></category>
		<category><![CDATA[List]]></category>
		<category><![CDATA[manufacturers]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[nations]]></category>
		<category><![CDATA[over]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[pharmacovigilance]]></category>
		<category><![CDATA[Pioglitazone]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[Profile]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulator]]></category>
		<category><![CDATA[risk]]></category>
		<category><![CDATA[ruffling]]></category>
		<category><![CDATA[Safety]]></category>
		<category><![CDATA[Section 26A]]></category>
		<category><![CDATA[states]]></category>
		<category><![CDATA[step]]></category>
		<category><![CDATA[study]]></category>
		<category><![CDATA[Sweden]]></category>
		<category><![CDATA[Takeda]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[UN]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[United]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[withdrawal]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2883</guid>
		<description><![CDATA[Recent order of the Indian drug regulator to withdraw all formulations of the well known, yet controversial, anti-diabetic drug &#8211; Pioglitazone from the domestic market has created a flutter in the country, ruffling many feathers at the same time. Withdrawal &#8230; <a href="http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pioglitazone-conundrum-should-the-drug-regulator-step-over-the-line/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>Pharma Innovation Absolutely Critical: But NOT Shorn from Ethics, Propriety, Compliance and Values</title>
		<link>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values</link>
		<comments>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/#comments</comments>
		<pubDate>Mon, 20 May 2013 00:00:08 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[apathy]]></category>
		<category><![CDATA[bribing]]></category>
		<category><![CDATA[Business]]></category>
		<category><![CDATA[buzzword]]></category>
		<category><![CDATA[Caesar]]></category>
		<category><![CDATA[Caesar's]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[compensation]]></category>
		<category><![CDATA[Compliance]]></category>
		<category><![CDATA[concealment]]></category>
		<category><![CDATA[corporate]]></category>
		<category><![CDATA[corrupt]]></category>
		<category><![CDATA[CT]]></category>
		<category><![CDATA[denigrating]]></category>
		<category><![CDATA[developed world]]></category>
		<category><![CDATA[doctors]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[economy]]></category>
		<category><![CDATA[Ethics]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Facts]]></category>
		<category><![CDATA[fall]]></category>
		<category><![CDATA[FCPA]]></category>
		<category><![CDATA[fines]]></category>
		<category><![CDATA[fixing]]></category>
		<category><![CDATA[foreign]]></category>
		<category><![CDATA[fraud]]></category>
		<category><![CDATA[generics]]></category>
		<category><![CDATA[globalized]]></category>
		<category><![CDATA[governance]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[grease]]></category>
		<category><![CDATA[guy]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[isolation]]></category>
		<category><![CDATA[leaders]]></category>
		<category><![CDATA[lower]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[management]]></category>
		<category><![CDATA[marketing]]></category>
		<category><![CDATA[middle]]></category>
		<category><![CDATA[Not]]></category>
		<category><![CDATA[OECD]]></category>
		<category><![CDATA[off-label]]></category>
		<category><![CDATA[overcharging]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[practices]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[propriety]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[religious]]></category>
		<category><![CDATA[scrutiny]]></category>
		<category><![CDATA[spiritual]]></category>
		<category><![CDATA[stakeholders]]></category>
		<category><![CDATA[suspicion]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[Talk]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trials]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[Values]]></category>
		<category><![CDATA[walk]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[wife]]></category>
		<category><![CDATA[X factors]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2481</guid>
		<description><![CDATA[Significant value added innovation is the bedrock of progress of the pharmaceutical industry and is essential for the patients. This is a hard fact. However, this current buzzword – ‘innovation’ can in no way be shorn from soft business necessities &#8230; <a href="http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/pharma-innovation-absolutely-critical-but-not-shorn-from-ethics-propriety-compliance-and-values/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>“New drug prices are Astronomical, Unsustainable and Immoral” – Anatomy of Unique Protests</title>
		<link>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests</link>
		<comments>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/#comments</comments>
		<pubDate>Mon, 06 May 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Access]]></category>
		<category><![CDATA[ACTH]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[anatomy]]></category>
		<category><![CDATA[astonishingly]]></category>
		<category><![CDATA[astronomical]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[center]]></category>
		<category><![CDATA[Clinical]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Conference]]></category>
		<category><![CDATA[Cowen]]></category>
		<category><![CDATA[diseases]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[dutch]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[expensive]]></category>
		<category><![CDATA[HBR]]></category>
		<category><![CDATA[Hunter]]></category>
		<category><![CDATA[immoral]]></category>
		<category><![CDATA[Index]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Ireland]]></category>
		<category><![CDATA[kettering]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[LSE]]></category>
		<category><![CDATA[medicine]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[memorial]]></category>
		<category><![CDATA[most]]></category>
		<category><![CDATA[Netherlands]]></category>
		<category><![CDATA[New]]></category>
		<category><![CDATA[NewYork]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Orphan]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[pompe]]></category>
		<category><![CDATA[price]]></category>
		<category><![CDATA[profiteering]]></category>
		<category><![CDATA[protests]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[rare]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[researchers]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[Sloan]]></category>
		<category><![CDATA[Syndrome]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapeutic]]></category>
		<category><![CDATA[to]]></category>
		<category><![CDATA[Trial]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[Union]]></category>
		<category><![CDATA[unique]]></category>
		<category><![CDATA[unsustainable]]></category>
		<category><![CDATA[upsurge]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2347</guid>
		<description><![CDATA[Yes. The quoted sentiment captured in the headline was reportedly voiced recently by many cancer specialists, including researchers and that too in the heartland of pharmaceutical innovation of the world– the United States of America. These specialist doctors argued: “High &#8230; <a href="http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/new-drug-prices-are-astronomicalunsustainable-and-immoral-anatomy-of-unique-protests/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>A Force Multiplier: An &#8220;Armageddon&#8221;: A Contender for Supremacy in the Generic Pharma World</title>
		<link>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world</link>
		<comments>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/#comments</comments>
		<pubDate>Mon, 22 Apr 2013 00:00:26 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[ANDAa]]></category>
		<category><![CDATA[API]]></category>
		<category><![CDATA[Armageddon]]></category>
		<category><![CDATA[Brazil]]></category>
		<category><![CDATA[BRIC]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[contender]]></category>
		<category><![CDATA[defend]]></category>
		<category><![CDATA[Department]]></category>
		<category><![CDATA[Developing]]></category>
		<category><![CDATA[DMFs]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[fastest]]></category>
		<category><![CDATA[force]]></category>
		<category><![CDATA[Frost&Sullivan]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[Glenmark]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Growing]]></category>
		<category><![CDATA[Guardian]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[infringing]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[multiplier]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[Non]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[perception]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Pharmacy]]></category>
		<category><![CDATA[Quality]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Sun]]></category>
		<category><![CDATA[supremacy]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Taro]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[triggering]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[UK-MHRA]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[World]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2193</guid>
		<description><![CDATA[It is very important for any country to ensure access to most appropriate medicines for the patients as and when they require. In many disease areas such access can be remarkably improved through affordable generic drugs, which offer significant savings &#8230; <a href="http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/a-force-multiplier-an-armageddon-a-contender-for-supremacy-in-the-generic-pharma-world/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>More Glivec Like Deals in China and Mounting Global Challenges: Innovators poised Joining Biosimilar Bandwagon</title>
		<link>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon</link>
		<comments>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/#comments</comments>
		<pubDate>Mon, 15 Apr 2013 00:00:04 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[12years]]></category>
		<category><![CDATA[AbVie]]></category>
		<category><![CDATA[advantage]]></category>
		<category><![CDATA[Amgen]]></category>
		<category><![CDATA[AstraZeneca]]></category>
		<category><![CDATA[bandwagon]]></category>
		<category><![CDATA[Barriers]]></category>
		<category><![CDATA[biologics]]></category>
		<category><![CDATA[biosimilar]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[companies]]></category>
		<category><![CDATA[Cost]]></category>
		<category><![CDATA[development]]></category>
		<category><![CDATA[drivers]]></category>
		<category><![CDATA[DRL]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EliLilly]]></category>
		<category><![CDATA[entry]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Genentech]]></category>
		<category><![CDATA[Glivec]]></category>
		<category><![CDATA[global]]></category>
		<category><![CDATA[growth]]></category>
		<category><![CDATA[Health]]></category>
		<category><![CDATA[Herceptin]]></category>
		<category><![CDATA[Hospira]]></category>
		<category><![CDATA[Humira]]></category>
		<category><![CDATA[IMS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Innovators]]></category>
		<category><![CDATA[J&J]]></category>
		<category><![CDATA[joining]]></category>
		<category><![CDATA[LG]]></category>
		<category><![CDATA[low]]></category>
		<category><![CDATA[market]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Minister]]></category>
		<category><![CDATA[Novartis]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[Pfizer]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[products]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Remicade]]></category>
		<category><![CDATA[Rituxan]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Teva]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[USFDA]]></category>
		<category><![CDATA[win-win]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2164</guid>
		<description><![CDATA[Pressure from the emerging markets on pricing of patented products is mounting fast. This time the country involved is China. Recently, the Health Minister of China who stepped down last month after a seven-year stint in the top health job &#8230; <a href="http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/more-glivec-like-deals-in-china-and-mounting-global-challenges-innovators-poised-joining-biosimilar-bandwagon/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The R&amp;D Factor: “One of the Great Myths of the Industry&#8221;</title>
		<link>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-rd-factor-one-of-the-great-myths-of-the-industry</link>
		<comments>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/#comments</comments>
		<pubDate>Mon, 25 Mar 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[1 billion]]></category>
		<category><![CDATA[andrew]]></category>
		<category><![CDATA[android]]></category>
		<category><![CDATA[Deloitte]]></category>
		<category><![CDATA[discovery]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[economics]]></category>
		<category><![CDATA[factor]]></category>
		<category><![CDATA[Frost]]></category>
		<category><![CDATA[genome]]></category>
		<category><![CDATA[global. CEO]]></category>
		<category><![CDATA[greatest]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[industry]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[it]]></category>
		<category><![CDATA[London]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[myths]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[one]]></category>
		<category><![CDATA[Open]]></category>
		<category><![CDATA[OS]]></category>
		<category><![CDATA[Pharmaceuticals]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reuters]]></category>
		<category><![CDATA[School]]></category>
		<category><![CDATA[sequencing]]></category>
		<category><![CDATA[Sullivan]]></category>
		<category><![CDATA[sustainability]]></category>
		<category><![CDATA[sustainable]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[the]]></category>
		<category><![CDATA[Thomson]]></category>
		<category><![CDATA[Tuft]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[vindication]]></category>
		<category><![CDATA[witty]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2085</guid>
		<description><![CDATA[Yes, that is what the global CEO of one of the Pharmaceutical giants of the world commented in a very recent interview with Reuters. Adding further to this comment he said, “US $1 billion price tag for R&#38;D was an &#8230; <a href="http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-rd-factor-one-of-the-great-myths-of-the-industry/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>To Curb Pharma Marketing Malpractices in India Who Bells the Cat?</title>
		<link>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat</link>
		<comments>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/#comments</comments>
		<pubDate>Mon, 18 Mar 2013 00:00:37 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[America]]></category>
		<category><![CDATA[and]]></category>
		<category><![CDATA[Australia]]></category>
		<category><![CDATA[bribe]]></category>
		<category><![CDATA[cat]]></category>
		<category><![CDATA[commission]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[curb]]></category>
		<category><![CDATA[curbing]]></category>
		<category><![CDATA[disclosure]]></category>
		<category><![CDATA[DoP]]></category>
		<category><![CDATA[E&Y]]></category>
		<category><![CDATA[financial]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[Healthcare]]></category>
		<category><![CDATA[HHS]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[indictment]]></category>
		<category><![CDATA[inertia]]></category>
		<category><![CDATA[interest]]></category>
		<category><![CDATA[intriguing]]></category>
		<category><![CDATA[Japan]]></category>
		<category><![CDATA[Jyoti]]></category>
		<category><![CDATA[Law]]></category>
		<category><![CDATA[Malpractices]]></category>
		<category><![CDATA[Mirdha]]></category>
		<category><![CDATA[MoH]]></category>
		<category><![CDATA[mouse]]></category>
		<category><![CDATA[Netherlands]]></category>
		<category><![CDATA[Obama]]></category>
		<category><![CDATA[Parliament]]></category>
		<category><![CDATA[Parliamentary]]></category>
		<category><![CDATA[Patient]]></category>
		<category><![CDATA[Payment]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Physician]]></category>
		<category><![CDATA[Planning]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reform]]></category>
		<category><![CDATA[slovakia]]></category>
		<category><![CDATA[Standing]]></category>
		<category><![CDATA[Sunshine]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[transparency]]></category>
		<category><![CDATA[UCPMP]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[US]]></category>
		<category><![CDATA[USA]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=2050</guid>
		<description><![CDATA[Bribing doctors by the pharmaceutical companies directly or indirectly, as reported frequently by the media all over the world, including India, to prescribe their respective brand of drugs has now reached an alarming proportion, jeopardizing patients’ interest, seriously more than &#8230; <a href="http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/to-curb-pharma-marketing-malpractices-in-india-who-bells-the-cat/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>An El Dorado&#8230;But Not Without Responsible Pricing:The Cancer Segment in India</title>
		<link>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area</link>
		<comments>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/#comments</comments>
		<pubDate>Mon, 04 Feb 2013 00:00:56 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[area]]></category>
		<category><![CDATA[BMS]]></category>
		<category><![CDATA[breast]]></category>
		<category><![CDATA[British]]></category>
		<category><![CDATA[cancer]]></category>
		<category><![CDATA[cervical]]></category>
		<category><![CDATA[China]]></category>
		<category><![CDATA[Cipla]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[Eldorado]]></category>
		<category><![CDATA[female]]></category>
		<category><![CDATA[gold]]></category>
		<category><![CDATA[Government]]></category>
		<category><![CDATA[GSK]]></category>
		<category><![CDATA[hamied]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[innovation]]></category>
		<category><![CDATA[investments]]></category>
		<category><![CDATA[Lancet]]></category>
		<category><![CDATA[lung]]></category>
		<category><![CDATA[male]]></category>
		<category><![CDATA[Medicines]]></category>
		<category><![CDATA[Merck]]></category>
		<category><![CDATA[Natco]]></category>
		<category><![CDATA[NICE]]></category>
		<category><![CDATA[NLEM]]></category>
		<category><![CDATA[NPPP2012]]></category>
		<category><![CDATA[oncology]]></category>
		<category><![CDATA[oral]]></category>
		<category><![CDATA[ovarian]]></category>
		<category><![CDATA[ovary]]></category>
		<category><![CDATA[pancreatic]]></category>
		<category><![CDATA[patented]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[pot]]></category>
		<category><![CDATA[pots]]></category>
		<category><![CDATA[PPP]]></category>
		<category><![CDATA[Pricing]]></category>
		<category><![CDATA[Product]]></category>
		<category><![CDATA[R&D]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[responsible]]></category>
		<category><![CDATA[right]]></category>
		<category><![CDATA[Roche]]></category>
		<category><![CDATA[rural]]></category>
		<category><![CDATA[Sanofi]]></category>
		<category><![CDATA[segment]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[therapy]]></category>
		<category><![CDATA[UK]]></category>
		<category><![CDATA[urban]]></category>
		<category><![CDATA[USA]]></category>
		<category><![CDATA[WHO]]></category>
		<category><![CDATA[yusuf]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=1493</guid>
		<description><![CDATA[The affordability issue for cancer treatment has been the subject of a raging debate since quite some time, as the incidence of cancer is fast increasing across the world. Just for example a very recent report highlighted that cancer has now become the &#8230; <a href="http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/right-pricing-holds-the-key-to-fetch-pots-of-gold-from-cancer-therapy-area/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
